Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

http://www.wikidata.org/entity/Q34489699

about

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial Hypometabolism as a therapeutic target in Alzheimer's disease Insulin in central nervous system: more than just a peripheral hormone PPAR-gamma: Therapeutic Potential for Multiple Sclerosis Thiazolidinediones for dementia and mild cognitive impairment Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders Brain fuel metabolism, aging, and Alzheimer's disease Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease Current Research Therapeutic Strategies for Alzheimer's Disease Treatment Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal Type 2 diabetes and cognitive impairment: linking mechanisms Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention Epidemiology of Alzheimer disease New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma Triad of Risk for Late Onset Alzheimer's: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome Mechanisms underlying inflammation in neurodegeneration Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.Type 2 diabetes and Alzheimer's disease: from common pathologies to potential new therapeutics.Pathogenesis of Alzheimer's disease Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.Cognitive dysfunction and diabetes mellitus Apolipoprotein E isoform-specific effects on lipoprotein receptor processing.

P2860

Q21245063-9236D264-7F48-4A9E-AA8A-3D8E0A3DE438 Q21262020-F7283436-5E31-4081-99F5-7799A41EFD34 Q21296648-639978AF-5FA0-467A-BE36-61F747DA0F97 Q21342822-71BC9C15-66FF-430F-B54F-0C5C9B5B0ADD Q24242116-A3866BB9-58DE-4DE6-82E1-346061006FCB Q24562763-3C0451B5-ABD6-4DAB-8F96-C9EA70F3C6AD Q24625859-FA4CEF19-2128-4397-A754-BBE6BC4C0C06 Q24628969-33E390E1-CD02-47C8-8E3F-B6236D3B2750 Q24646616-81718865-F782-4797-AC01-E66EE119B16C Q24652687-343E2858-E311-43F5-AA98-E2FBAD493DD8 Q24657243-F96AD496-8CB3-4685-BB26-915477EA4B6D Q26765530-F5F672BF-38AD-4E05-9143-75BA38DC48D7 Q26783344-FF6666A3-077F-44C8-AD17-456F3E51A70D Q26822993-14B157BE-555D-4606-BBD6-91FBCDBF4A36 Q26830845-4D5259EC-E294-469C-BCBF-61B7D9DC08B3 Q26860246-0AF60EEE-F2A3-466E-8843-FF7C2015FA5B Q26865358-AF83B6EA-2652-4CCB-BC42-F6C6E65F3FDA Q26865371-D8C10E73-F23D-4998-96B5-28E439FC1648 Q26866006-875A09A7-1628-4049-BDFF-8AEA01D284FB Q27003253-66FE2188-0C0C-4E54-A81D-DA68F3F4959B Q27008997-DC40DF4E-72C2-42ED-B854-DD4E8A2B185B Q27021700-DC4E9094-5ACD-44BE-BF6E-0D7F3043FCD4 Q27338799-3D14E6B4-85DE-411B-85C4-E3E73654B55A Q28069549-394A9132-E70B-4AB6-8F94-2F4210F01292 Q28075617-3613817B-A2F5-4D69-88AC-204B8F183D6C Q28077056-8C2101A9-3E54-45B2-8E15-C991F872CAA8 Q28083039-C7B75BA7-7737-4438-AA0D-91AD5019AE82 Q28085213-8B2F4D77-A653-425B-B630-9DC3E3176180 Q28086892-3ED1F78B-8839-48FC-A389-83B2000BFCAC Q28259585-8075962E-9F6C-4D97-919D-6E2C023D93D8 Q28308082-F5B4E70F-6679-45F6-848F-0FE9A11C8DBA Q28742884-85023247-3A45-45C7-BA21-8FD723161D57 Q28822352-D37DD4F3-E51B-48AC-ADD9-ECF576A708CE Q29617977-BAFF75BF-0737-44F7-A43B-B0E906134283 Q30357397-9CB05DBE-2134-443F-8177-E5F5339EDAEB Q30438004-799EFDC2-DAA1-4FB6-93D5-2B66F11E642D Q30439489-C74C89FE-2F4C-47B3-857B-ADAB6337DBE1 Q30471693-485449DD-8746-406E-AEE0-BD2CF83172BF Q30489305-50324D8B-623A-4391-A3C8-22FCE6FB8FC6 Q33112703-35DA1D8C-D658-4A82-A3FC-85BB114999CE

P2860

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

http://www.wikidata.org/entity/Q34489699

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@ast

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@en

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@nl

type

label

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@ast

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@en

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@nl

prefLabel

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@ast

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@en

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@nl

P1433

Q34489699-FA30EFA4-58EB-48BB-B612-B651CCF999B8

P1476

Q34489699-0EB2EAFF-1D4B-488E-B0BE-F799B3870094

P2093

Q34489699-0A5F8DE0-A8BC-496E-81C7-E48F9FA2F9B5

Q34489699-185C6CE7-B0EA-416C-BE9B-DF0B30C9244C

Q34489699-3F436F5B-71EA-41E3-9FFB-FBF23F956A38

Q34489699-6A62593E-1326-4C3A-9464-607005110CB6

Q34489699-8A8F4646-5C7D-411E-A020-27C6B0E6F65D

Q34489699-8B4463AF-87C5-4E44-8D66-BB46E4B20926

Q34489699-A98C9961-91D2-432B-9E75-24192752FE6D

Q34489699-D74E8E7B-4575-4820-9BF8-8E92A79FDCC8

Q34489699-DE8E7FB4-0772-4ECE-88EC-B66B0555BD98

Q34489699-F9A17216-3564-430B-9F9D-4B6318798E0B

P2888

Q34489699-4382D53D-D565-490A-BF18-C303DEB0EB9B

P304

Q34489699-0FD52360-B9B8-4006-AEA3-B198E24F9204

P31

Q34489699-E679B316-5D55-46C8-9894-213A9E9DE001

P356

Q34489699-9224A7FD-ED88-4F57-8075-1B1DCA45B65B

P433

Q34489699-53BC20C7-C1D0-4B93-BB30-651868FCE7E8

P478

Q34489699-F7470223-3E59-4722-9776-2AB8112E4406

P577

Q34489699-9E47AC9F-FC10-4CE3-BFA0-CB8D2385CA03

P5875

Q34489699-197BE149-54DA-4DAD-BC70-6D6103A711B5

P6179

Q34489699-FE104F27-C39C-41DD-A4AA-78BA6BE638CD

P698

Q34489699-A93A775A-EF6B-44E7-AD38-1EC0A699D621

P921

Q34489699-E01C34A2-6831-4160-A434-2347635D10C9

P356

P1433

The Pharmacogenomics Journal

P1476

Efficacy of rosiglitazone in a ...... -moderate Alzheimer's disease.

@en

P2093

A D Roses

http://www.w3.org/2001/XMLSchema#string

A M Saunders

http://www.w3.org/2001/XMLSchema#string

D A Hosford

http://www.w3.org/2001/XMLSchema#string

G C Ormandy

http://www.w3.org/2001/XMLSchema#string

I M Foley

http://www.w3.org/2001/XMLSchema#string

J F B Altman

http://www.w3.org/2001/XMLSchema#string

M E Risner

http://www.w3.org/2001/XMLSchema#string

M E Zvartau-Hind

http://www.w3.org/2001/XMLSchema#string

Rosiglitazone in Alzheimer's Disease Study Group

http://www.w3.org/2001/XMLSchema#string

S Craft

http://www.w3.org/2001/XMLSchema#string

P2888

P304

246-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.TPJ.6500369

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7326682

http://www.w3.org/2001/XMLSchema#string

P6179

1037923527

http://www.w3.org/2001/XMLSchema#string

P698

16446752

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease